Free Trial

Sight Sciences Q3 2023 Earnings Report

Sight Sciences logo
$2.29 -0.11 (-4.58%)
As of 04:00 PM Eastern

Sight Sciences EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Sight Sciences Revenue Results

Actual Revenue
$20.01 million
Expected Revenue
$20.51 million
Beat/Miss
Missed by -$500.00 thousand
YoY Revenue Growth
N/A

Sight Sciences Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Sight Sciences Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Sight Sciences (SGHT) Receives a Hold from Piper Sandler
See More Sight Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sight Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sight Sciences and other key companies, straight to your email.

About Sight Sciences

Sight Sciences (NASDAQ:SGHT), an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

View Sight Sciences Profile

More Earnings Resources from MarketBeat